United Therapeutics Presents Data at The European Society of Cardiology Congress 2026 and The European Respiratory Society International Congress 2026
ADVANCE OUTCOMES presentations include an analysis showing that ralinepag achieved clinical improvement in a lower risk pulmonary arterial hypertension (PAH) population and reduced clinical worsening in PAH patients with connective tissue disease, in which underlying vascular remodeling and endothelial dysfunction may be accelerated, making PAH more difficult to treat
TETON presentations include analyses showing that nebulized treprostinil improved lung function, demonstrated a consistent benefit in reducing serious clinical worsening events, and showed a dose-dependent magnitude of benefit compared to placebo in idiopathic pulmonary fibrosis (IPF) patients
Additional presentations feature interim data from the ARTISAN study of parenteral treprostinil in PAH patients and preliminary data from PHINDER, a first of its kind study designed to improve screening for pulmonary hypertension associated with interstitial lung disease (PH-ILD)
SILVER SPRING, Md. & RESEARCH TRIANGLE PARK, N.C, August 28, 2026--United Therapeutics Corporation (Nasdaq: UTHR), a public benefit corporation, today announced that four oral presentations and four poster presentations will be presented across its commercial and development portfolio at the European Society of Cardiology (ESC) Congress 2026, August 28-31 in Munich, and at the European Respiratory Society (ERS) Congress 2026, September 5-9 in Barcelona.
The presentations include late-breaking analyses from the phase 3 ADVANCE OUTCOMES study of investigational ralinepag in PAH, the phase 3 TETON clinical program evaluating nebulized treprostinil in IPF, and the ARTISAN study evaluating parenteral treprostinil in PAH, as well as preliminary data from the PHINDER study in PH-ILD.
"This year at ERS and ESC, we are presenting data that reflect the breadth of our work to deepen our understanding of how appropriate treatment may improve outcomes for people living with life-threatening diseases like PAH, PH-ILD, and IPF. We remain committed to generating meaningful evidence across both established and investigational therapies to help advance the standard of care for these patient populations," said Franck Rahaghi, M.D., Chief Medical Officer, United Therapeutics.
Treatment with Ralinepag Improves Outcomes in Patients with Connective Tissue Disease Associated with Pulmonary Arterial Hypertension: Results from the Phase 3 ADVANCE OUTCOMES Study
Late-breaking Oral Presentation, Saturday, August 29, 11:00 - 11:15 AM CEST. Presented by George Giannakoulas, M.D., Ph.D., Thessaloniki, Greece.